Earnings ·
Immuron Limited reported FY26 sales of AUD$7.7 million, representing a 6% increase compared to the prior comparative…
IMRNImmuron Ltd
Immuron Limited reported FY26 sales of AUD$7.7 million, representing a 6% increase compared to the prior comparative period. Regional performance included AUD$5.8 million in Australia (+10% pcp), AUD$1.8 million in the USA (+7% pcp), and AUD$0.2 million in Canada (-55% pcp). Despite the decline in Canada, the company noted a 376% increase in Canadian sales during 4Q FY26. Growth was driven by digital marketing, increased store presence, and rising Southeast Asian travel. The company operates in the biopharmaceutical industry, developing and commercializing orally delivered polyclonal antibodies for infectious diseases.